P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV)

Detalles Bibliográficos
Autores principales: Seefat, M.R., Stege, C.A.M., Timmers, G.J., Levin, M.D., Hoogendoorn, M., Ypma, P.F., Nijhof, I.S., Velders, G.A., Strobbe, L., Durdu-Rayman, N., Westerman, M., Davidis-van Schoonhoven, M.A., van Kampen, R.J.W., Beeker, A., Koster, A., Dijk, A.C., van de Donk, N.W.C.J., van der Spek, E., Leys, M.B.L., Silbermann, M.H., Groen, K., van der Burg-de Graauw, N.C.H.P., Sinnige, H.A.M., van der Hem, K.G., Levenga, T.H., Bilgin, Y.M., Sonneveld, P., Klein, S.K., Nasserinejad, K., Blommestein, H.M., Cucchi, D.G.J., Lissenberg-Witte, B.I., Zweegman, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Poster
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171826/
http://dx.doi.org/10.1097/01.HS9.0000936176.74423.76
_version_ 1785039506593808384
author Seefat, M.R.
Stege, C.A.M.
Timmers, G.J.
Levin, M.D.
Hoogendoorn, M.
Ypma, P.F.
Nijhof, I.S.
Velders, G.A.
Strobbe, L.
Durdu-Rayman, N.
Westerman, M.
Davidis-van Schoonhoven, M.A.
van Kampen, R.J.W.
Beeker, A.
Koster, A.
Dijk, A.C.
van de Donk, N.W.C.J.
van der Spek, E.
Leys, M.B.L.
Silbermann, M.H.
Groen, K.
van der Burg-de Graauw, N.C.H.P.
Sinnige, H.A.M.
van der Hem, K.G.
Levenga, T.H.
Bilgin, Y.M.
Sonneveld, P.
Klein, S.K.
Nasserinejad, K.
Blommestein, H.M.
Cucchi, D.G.J.
Lissenberg-Witte, B.I.
Zweegman, S.
author_facet Seefat, M.R.
Stege, C.A.M.
Timmers, G.J.
Levin, M.D.
Hoogendoorn, M.
Ypma, P.F.
Nijhof, I.S.
Velders, G.A.
Strobbe, L.
Durdu-Rayman, N.
Westerman, M.
Davidis-van Schoonhoven, M.A.
van Kampen, R.J.W.
Beeker, A.
Koster, A.
Dijk, A.C.
van de Donk, N.W.C.J.
van der Spek, E.
Leys, M.B.L.
Silbermann, M.H.
Groen, K.
van der Burg-de Graauw, N.C.H.P.
Sinnige, H.A.M.
van der Hem, K.G.
Levenga, T.H.
Bilgin, Y.M.
Sonneveld, P.
Klein, S.K.
Nasserinejad, K.
Blommestein, H.M.
Cucchi, D.G.J.
Lissenberg-Witte, B.I.
Zweegman, S.
author_sort Seefat, M.R.
collection PubMed
description
format Online
Article
Text
id pubmed-10171826
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-101718262023-05-11 P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV) Seefat, M.R. Stege, C.A.M. Timmers, G.J. Levin, M.D. Hoogendoorn, M. Ypma, P.F. Nijhof, I.S. Velders, G.A. Strobbe, L. Durdu-Rayman, N. Westerman, M. Davidis-van Schoonhoven, M.A. van Kampen, R.J.W. Beeker, A. Koster, A. Dijk, A.C. van de Donk, N.W.C.J. van der Spek, E. Leys, M.B.L. Silbermann, M.H. Groen, K. van der Burg-de Graauw, N.C.H.P. Sinnige, H.A.M. van der Hem, K.G. Levenga, T.H. Bilgin, Y.M. Sonneveld, P. Klein, S.K. Nasserinejad, K. Blommestein, H.M. Cucchi, D.G.J. Lissenberg-Witte, B.I. Zweegman, S. Hemasphere Poster Lippincott Williams & Wilkins 2023-05-09 /pmc/articles/PMC10171826/ http://dx.doi.org/10.1097/01.HS9.0000936176.74423.76 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Poster
Seefat, M.R.
Stege, C.A.M.
Timmers, G.J.
Levin, M.D.
Hoogendoorn, M.
Ypma, P.F.
Nijhof, I.S.
Velders, G.A.
Strobbe, L.
Durdu-Rayman, N.
Westerman, M.
Davidis-van Schoonhoven, M.A.
van Kampen, R.J.W.
Beeker, A.
Koster, A.
Dijk, A.C.
van de Donk, N.W.C.J.
van der Spek, E.
Leys, M.B.L.
Silbermann, M.H.
Groen, K.
van der Burg-de Graauw, N.C.H.P.
Sinnige, H.A.M.
van der Hem, K.G.
Levenga, T.H.
Bilgin, Y.M.
Sonneveld, P.
Klein, S.K.
Nasserinejad, K.
Blommestein, H.M.
Cucchi, D.G.J.
Lissenberg-Witte, B.I.
Zweegman, S.
P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV)
title P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV)
title_full P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV)
title_fullStr P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV)
title_full_unstemmed P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV)
title_short P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV)
title_sort p12 health-related quality of life in frail and intermediate-fit patients with newly diagnosed multiple myeloma treated with dose-adjusted melphalan-prednisone-bortezomib (mpv)
topic Poster
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171826/
http://dx.doi.org/10.1097/01.HS9.0000936176.74423.76
work_keys_str_mv AT seefatmr p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT stegecam p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT timmersgj p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT levinmd p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT hoogendoornm p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT ypmapf p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT nijhofis p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT veldersga p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT strobbel p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT durduraymann p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT westermanm p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT davidisvanschoonhovenma p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT vankampenrjw p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT beekera p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT kostera p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT dijkac p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT vandedonknwcj p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT vanderspeke p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT leysmbl p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT silbermannmh p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT groenk p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT vanderburgdegraauwnchp p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT sinnigeham p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT vanderhemkg p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT levengath p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT bilginym p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT sonneveldp p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT kleinsk p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT nasserinejadk p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT blommesteinhm p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT cucchidgj p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT lissenbergwittebi p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv
AT zweegmans p12healthrelatedqualityoflifeinfrailandintermediatefitpatientswithnewlydiagnosedmultiplemyelomatreatedwithdoseadjustedmelphalanprednisonebortezomibmpv

Ejemplares similares